Fundraising Fox

Nocion Therapeutics

Watertown, US · Founded 2017 · Delaware corporation · 5 known investors

nociontx.com ↗

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.

BiotechHealthtechMedical Devicesin /nocion-therapeutics-inc@nociontx

Founders & leadership

VM
VIJAY MURTHYDirector
PO
PINI ORBACHDirector
RH
ROSY HUDirector
MF
MATTHEW FRANKELExecutive Officer
PCPETER COUROSSI
PETER COUROSSIExecutive Officer
RB
RICHARD BATYCKYExecutive Officer, Director
JE
JAMES ELLISExecutive Officer
FD
FREDDIE DEARDirector
MH
MICHAEL HIGGINSDirector
MF
MEREDITH FISHERDirector
JA
JESSICA ALSTONDirector
ML
MICHAEL LIPPExecutive Officer

Investors · 5

Canaan Partners✓ verifiedStamford · $500K – $20Mvia Julie Grant · board
F-Prime Capital PartnersCambridge · $3M – $10M
Mission BiocapitalSan Francisco · $500K
Monograph Capital PartnersLondonvia Freddie Dear · board
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

Reported raises · per SEC filings

Form D private placements
▶$23MraisedMar 2026 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • VIJAY MURTHYDirector
  • JULIE GRANTDirector
  • PINI ORBACHDirector
  • ROSY HUDirector
  • MATTHEW FRANKELExecutive Officer
  • PETER COUROSSIExecutive Officer
  • RICHARD BATYCKYExecutive Officer, Director
  • JAMES ELLISExecutive Officer
  • FREDDIE DEARDirector
  • MICHAEL HIGGINSDirector
Offering amount
$23M
Amount sold
$23M
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$31.1MraisedMar 2024 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JULIE GRANTDirector
  • ROSY HUDirector
  • BERNARD SILVERMANExecutive Officer
  • RICHARD BATYCKYExecutive Officer, Director
  • FREDDIE DEARDirector
  • PINI ORBACHDirector
  • PETER COUROSSIExecutive Officer
  • MICHAEL HIGGINSDirector
  • JAMES ELLISExecutive Officer
  • VIJAY MURTHYDirector
Offering amount
$70M
Amount sold
$31.1M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedAug 2022 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • JULIE PAPANEK GRANTDirector
  • BRIDGET M. COLEExecutive Officer
  • JESSICA ALSTONDirector
  • MICHAEL HIGGINSDirector
  • RICHARD BATYCKYExecutive Officer, Director
  • MICHAEL LIPPExecutive Officer
  • JONATHAN GARENExecutive Officer
  • MEREDITH FISHERDirector
  • JAMES ELLISExecutive Officer
  • CHRISTOPHER SILBERExecutive Officer
Offering amount
$17M
Amount sold
$7M
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedJan 2021 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL HIGGINSDirector
  • JULIE PAPANEK GRANTDirector
  • MEREDITH FISHERDirector
  • JESSICA ALSTONDirector
  • MICHAEL LIPPExecutive Officer
  • JAMES ELLISExecutive Officer
  • CHRISTOPHER SILBERExecutive Officer
  • RICHARD BATYCKYExecutive Officer, Director
  • BRIDGET M. COLEExecutive Officer
Offering amount
$25M
Amount sold
$15M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news